Cediranib (AZD217)

Short Summary : VEGFR inhibitor receptor,highly potent

Category : Tyrosine Kinase|VEGFR

Purity : 0.98

CAS Number : 288383-20-0

Formula : C25H27FN4O3

Molecular Weight : 450.51

SMILE : CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5

Solubility : >22.5mg/mL in DMSO

Storage : Store at -20°C

Description : Cediranib (also known as AZD2171) is a highly potent KDR tyrosine kinase inhibitor that ATP-competitively inhibits recombinant KDR tyrosine kinase as well as other members of vascular endothelial growth factor receptor (VEGFR) family, including Flt-1 (VEGFR-1) and Flt-4 (VEGFR-3) with the half maximal inhibition concentration IC50 values of Cediranib also potently inhibits a few members of platelet-derived growth factor receptor (PDGFR) family, including c-Kit, PDGFR-, PDGFR-, CSF-1R and Flt-3, with IC50 values of 0.002 mol/L, 0.005 mol/L, 0.036 mol/L, 0.11 mol/L anf > 1 mol/L respectively due to their similar structure to VEGFR family members [1].References:[1] Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jrgensmeier JM, Ogilvie DJ. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005 May 15;65(10):4389-400.

Download datasheet